SELLAS Life Sciences Group Inc (NAS:SLS)

$ 1.235 0.015 (1.23%) Market Cap: 71.33 Mil Enterprise Value: 53.71 Mil PE Ratio: 0 PB Ratio: 7.26 GF Score: 41/100

Sellas Life Sciences Group Inc Corporate Update Call Transcript
Jan 03, 2024
Sellas Life Sciences Group Inc Expert Panel Discussion Transcript
May 30, 2023
Sellas Life Sciences Group Inc to Host Key Opinion Leader Webinar Transcript
Jan 31, 2023
Sellas Life Sciences Group Inc Galinpepimut-S Update Call Transcript
Nov 14, 2022
Sellas Life Sciences Group Inc Galinpepimut-S Update Call Transcript
Sep 15, 2022
Sellas Life Sciences Group Inc Provides Business Update and First Quarter 2022 Highlights Transcript
Apr 06, 2022
Sellas Life Sciences Group Inc Virtual Investor Symposium Corporate Call Transcript
Aug 17, 2021
Sellas Life Sciences Group Inc Shareholder Update Call Transcript
Jun 03, 2021
Sellas Life Sciences Group Inc Annual Shareholders Meeting Transcript
Jun 09, 2020
Sellas Life Sciences Group Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 18, 2020
Sellas Life Sciences Group Inc Corporate Analyst Meeting Transcript
Nov 15, 2019

Sellas Life Sciences Group Inc Expert Panel Discussion Transcript

May 30, 2023 / 12:00PM GMT

Release Date Price: $1.73 (+2.68%)

Transcript

Operator

(technical difficulty) panel discussion. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the event.

I'd now like to turn the call over to your host, Dr. Angelos Stergiou, Founder, President and Chief Executive Officer of SELLAS Life Sciences Group. Please go ahead, Angelos.

Angelos M. Stergiou

SELLAS Life Sciences Group, Inc. - Founder, President, CEO & Director

Thank you, and good morning, everyone, and welcome to SELLAS' GFH009 expert panel call. First, thank you for your participation and support in joining us today. We're very excited to take this time to focus on some important developments regarding the GFH009 program, particularly around the upcoming Phase IIa relapsed/refractory AML study and very pleased with FDA's comments and inputs to our trial design.

It is my pleasure to also be joined by doctors Kadia, Zeidner and Jamy as well as our Senior Vice President of Clinical Development, Dr. Dragan Cicic, and our Senior Vice

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.